Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: A multicenter real-world study

In a retrospective multicenter study, researchers evaluated the efficacy of everolimus in different treatment lines for patients with HR+ HER2- advanced breast cancer. They found that progression-free survival was significantly worse from first-line to second-line to third-line treatment (13.5 months vs. 6.1 months vs. 4.1 months, respectively).